Clinical Trial Update: A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI [Phase 3]

View source ↗

Summary

Phase 3 trial comparing REG1 to bivalirudin in patients undergoing percutaneous coronary intervention was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Bivalirudin (bivalirudin)
• REG1

Snippet

Sponsor: Regado Biosciences, Inc. | Conditions: Coronary Artery Disease | Phase 3 | Status: TERMINATED